Oncogenic miR-9 is a target of erlotinib in NSCLCs

EGFR-targeted cancer therapy is a breakthrough in non-small cell carcinoma. miRNAs have been proved to play important roles in cancer. Currently, for the role of miRNAs in EGFR-targeted cancer therapy is unclear. In this study, first we found that erlotinib reduced the expression of miR-9. MiR-9 exp...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xi, Zhu, Lingjun, Ma, Zhuo, Sun, Geng, Luo, Xuan, Li, Min, Zhai, Sulan, Li, Ping, Wang, Xuerong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4655475/
https://www.ncbi.nlm.nih.gov/pubmed/26593208
http://dx.doi.org/10.1038/srep17031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4655475/
https://www.ncbi.nlm.nih.gov/pubmed/26593208
http://dx.doi.org/10.1038/srep17031

Ejemplares similares